How to Model a Telehealth Startup P&L

A telehealth startup P&L is not a mystery — it is five levers: revenue per patient, cost of goods, customer acquisition cost, retention, and fixed overhead. Gross margins on compounded cash-pay medications are high, so the business is won or lost on the last two — acquisition and retention — not on drug cost. The number that decides survival is lifetime contribution margin against blended CAC, not the margin on any single order.

This is a model walkthrough for operators, not financial advice. It builds the P&L line by line, shows why the first order is usually unprofitable by design, and identifies the metric — LTV:CAC — that tells you whether the business compounds or bleeds. It sits directly on top of the unit-economics foundation; this post assembles those units into a full statement.

---

What Are the Line Items in a Telehealth P&L?

Five groups. Revenue is order value times refill frequency across a patient's lifetime. Cost of goods is the pharmacy's compounding charge, shipping, provider approval, and any platform or fulfillment fee. Below that sit customer acquisition cost and fixed overhead — software, compliance, licensing, and salaries. Everything analytically important is derived from these: contribution margin per order and lifetime value against CAC.

The order of the list is also the order of leverage. Revenue and COGS set your gross margin, which for cash-pay compounded medicine is structurally high. But two clinics with identical gross margins can have opposite outcomes depending on what they pay to acquire a patient and how long that patient stays. So while the P&L has many lines, the ones that move the outcome cluster at the bottom — acquisition and retention. Keep that hierarchy in mind as we build each block.

---

How Do You Build the Revenue Line?

Revenue per patient is average order value multiplied by the number of orders a retained patient places. A $199 monthly compounded subscription is not $199 of revenue — it is $199 times however many months the patient stays. That reframing is the whole point: in a subscription model, revenue is a function of retention, so the revenue line and the retention assumption are inseparable.

Model revenue as a cohort, not a transaction:

• Average order value (AOV). The cash price of a typical order, blended across your catalog.
• Refill frequency. How often a retained patient reorders (monthly is common for compounded hormones and GLP-1).
• Retained lifetime. The average number of orders before churn — the single most sensitive input in the model.
• Expansion. Whether patients add categories over time (e.g., a TRT patient adding a peptide), which lifts AOV.

Because retained lifetime swings revenue so hard, sensitivity-test it. A model that assumes six refills and delivers three is not off by a little — it has roughly halved lifetime revenue per patient.

---

What Goes Into Cost of Goods and Contribution Margin?

Cost of goods for an order is the pharmacy compounding and dispensing charge, shipping (higher for cold-chain injectables), the licensed provider's approval cost, and any flat platform or fulfillment fee. Subtract all of it from the order's revenue and you get contribution margin per order — the cash each order actually throws off before acquisition and overhead.

Contribution margin, not gross margin, is the operating number. Here is the per-order block for an illustrative cash-pay subscription:

Line item	Per order	Share of price
Order revenue (AOV)	$199	100%
Pharmacy compounding + dispensing	$35	18%
Shipping / cold chain	$20	10%
Provider approval	$15	8%
Platform / fulfillment fee (flat)	$5	2%
Contribution margin per order	$124	62%

That $124 is what pays back acquisition cost and funds overhead. Note the platform fee is flat and small — modeled as a fair-market per-order charge rather than a percentage of the drug's value, which keeps the structure clean. The gross-margin context is in where telehealth gross margins land.

---

Why Is the First Order Usually Unprofitable?

Because acquisition cost lands entirely on order one. If blended CAC is $180 and the first order contributes $124, the patient is $56 underwater after their first purchase. That is not a broken model — it is how subscription direct-to-consumer works. The clinic is buying a stream of high-margin refills, and it pays for the whole stream at the start.

The implication is that first-order margin is the wrong scoreboard. A clinic optimizing to make order one profitable will underinvest in acquisition and starve its own growth; a clinic that ignores payback entirely will run out of cash before the refills arrive. The correct frame is payback period and lifetime value. In the example above, the patient crosses into profit on the second refill and compounds from there — so the question is not "is order one profitable" but "how many orders until payback, and how long does the patient stay." Category-level inputs for this live in CAC and LTV benchmarks by category.

---

What Does the Whole Model Look Like Per Patient?

Assemble the pieces into a lifetime view and the P&L becomes legible. Take the $124 contribution per order, multiply by retained order count, subtract blended CAC once, and you have lifetime contribution per patient — the amount each acquired patient contributes toward overhead and profit.

Metric	Value	How it is derived
Contribution margin per order	$124	Revenue minus all variable costs
Retained orders per patient	6	Average orders before churn
Lifetime contribution (gross)	$744	$124 x 6
Blended CAC	$180	Total acquisition spend / patients won
Lifetime contribution (net of CAC)	$564	$744 minus $180
LTV:CAC ratio	~4.1:1	$744 / $180

This single table is the business. A ~4:1 LTV:CAC clears the common 3:1 health benchmark, meaning each patient funds overhead and profit comfortably. Change two inputs — push CAC to $300 or retained orders down to three — and the same clinic slips below break-even. The model's fragility lives in exactly the two levers this guide has emphasized.

---

Which Levers Actually Decide Survival?

Retention and acquisition cost. Because gross margin is high and largely fixed by the category, the outcome turns on how cheaply you acquire patients and how long you keep them. A clinic that lifts retained orders from three to six roughly doubles lifetime contribution without spending another dollar on acquisition; a clinic that lets CAC drift up erases its margin regardless of how good the drug economics look.

Three operating priorities follow directly:

1. Defend retention first. Auto-refill, adherence support, and a frictionless reorder flow move lifetime value more than any pricing tweak. See how retention drives the subscription model.
2. Watch payback, not first-order margin. Track weeks-to-payback and hold blended CAC to a level your contribution margin can recover within a few refills.
3. Keep variable costs negotiable. Owning your pharmacy relationship and patient data means you can re-route or re-price if a cost line moves — a P&L with locked-in variable costs is a fragile one.

---

Key Takeaways

• A telehealth P&L reduces to five levers: revenue per patient, COGS, CAC, retention, and fixed overhead.
• Gross margins are high (60-80%), so the model is won on acquisition cost and retention, not on drug cost.
• Contribution margin per order — revenue minus all variable costs — is the operating number, not gross margin.
• The first order is usually unprofitable by design; LTV:CAC and payback period are the real health metrics.
• 3:1 LTV:CAC is the common benchmark for a sustainable subscription business.
• Owning your data and pharmacy relationship keeps variable costs negotiable, which separates a durable P&L from a fragile one.

---

Frequently Asked Questions

What are the main line items in a telehealth P&L?

Revenue (order value times refill frequency), cost of goods (pharmacy compounding, shipping, provider approval, platform fees), customer acquisition cost, and fixed overhead (software, compliance, licensing, salaries). The derived metrics that matter are contribution margin per order and lifetime value against blended CAC.

Why is my first order usually unprofitable?

Because acquisition cost is front-loaded onto order one. If it costs $180 to acquire a patient and the first order contributes $124, that patient is underwater until refills accumulate. This is normal for subscription DTC — the model earns its return across a retained lifetime, not on the first transaction.

What LTV:CAC ratio should a telehealth startup target?

3:1 is the widely cited benchmark for a healthy subscription business. Below roughly 1:1 you lose money on every patient; well above 3:1 may mean you are underinvesting in growth. The ratio, not any single order's margin, is the survival metric.

How does retention change the model?

Dramatically. Since acquisition is paid once and refills are high-margin, small retention gains produce large lifetime-value swings. Lifting refill count from three to six roughly doubles the gross profit per acquired patient without another dollar of acquisition spend.

---

neolife is the fulfillment rail that sits on top of the compounding pharmacy you already use, priced as a flat per-order fee — so the variable-cost line in your P&L stays small and negotiable, and your pharmacy relationship stays yours to re-price or re-route. If you want a stack whose economics you control, talk to us. This post is educational and not financial advice; build and stress-test your own model before making decisions.